{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:09Z","timestamp":1787020869257,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Participant Information Leaflets (PILs) are lengthy and increasingly complex, and could deter research participation. A shortened PIL may be more appealing as it is likely to provide a more a manageable volume of information. Previous research has found that shortened PILs are no less effective for recruitment outcomes, and we deemed it useful to replicate this in an online setting. We also decided to compare retention rates, given the potential for more information to increase participants\u2019 motivation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy of a shortened vs standard-length PIL on trial recruitment and retention rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This two-arm study within a trial (SWAT) was embedded in a host randomised controlled trial (RCT)\u2014IBD-BOOST.<\/jats:p>\n                    <jats:p>Potential participants were randomised to receive a standard-length or shortened PIL electronically for recruitment to the host RCT. An ethics committee approved potential participants being blinded to this randomisation.<\/jats:p>\n                    <jats:p>Primary outcome: The percentage of SWAT participants receiving the shortened vs standard PIL who were recruited to the RCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four thousand two hundred one participants were randomised to the standard-length (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092099) and shortened (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092102) PIL arms. Thirty-four email queries were received about the PILs\u201418 from those who received the standard and 16 from those receiving the shortened. Seven hundred eight SWAT participants were recruited to the RCT\u2014333 (15.86%) who received the standard-length PIL and 375 (17.84%) who received the shortened (OR\u2009=\u20091.15, (95%CI\u2009=\u20090.98, 1.35),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09). Retention rates in the RCT were not statistically different between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We did not find evidence of a significant difference between RCT recruitment and retention rates in participants randomised to the standard-length PIL compared with the shortened. It may be that a shortened PIL has the same effect on recruitment and retention outcomes, providing that the trial does not require extensive information for other reasons (e.g. safety). Therefore, it could be argued that researchers have a choice about how long to make PILs, perhaps with a link to more detail. Alternatively, given that there was no benefit of the shortened PIL, it may be worth comparing written PILs with other methods of conveying information to determine optimal means of encouraging participation and retention in decentralised trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Host trial registration<\/jats:title>\n                    <jats:p>A randomised controlled trial of supported, online, self-management for symptoms of fatigue, pain and urgency\/incontinence in people with inflammatory bowel disease: the IBD-BOOST trial (ISRCTN71618461 on ISRCTN registry).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-08931-6","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T18:34:02Z","timestamp":1750185242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["What is the impact on recruitment of a shortened compared with a standard-length participant information leaflet? PROMETHEUS in IBD-BOOST: study within a trial, a decentralised UK randomised controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"L.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cl\u00e9irigh-B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Arundel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hamborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McGuinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Moss-Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Relton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Wileman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zenasni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"8931_CR1","unstructured":"National Research Ethics Service, Information sheets and consent forms: guidance for researchers and reviewers. 2018."},{"key":"8931_CR2","unstructured":"Content: Participant Information Sheet: What\u2019s Involved - Consent and Participant information sheet preparation guidance. Health Research Authority. https:\/\/www.hra-decisiontools.org.uk\/consent\/content-sheet-involved.html."},{"key":"8931_CR3","unstructured":"Participant information design and review principles. Health Research Authority. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/research-planning\/participant-information-design-and-review-principles\/."},{"issue":"2","key":"8931_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jclinepi.2011.06.005","volume":"65","author":"G Brierley","year":"2012","unstructured":"Brierley G, Richardson R, Torgerson D. Using short information leaflets as recruitment tools did not improve recruitment: A randomized controlled trial. J Clin Epidemiol. 2012;65(2):147\u201354.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"8931_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076435","volume":"8","author":"HM Kirkby","year":"2013","unstructured":"Kirkby HM, et al. Informing potential participants about research: Observational study with an embedded randomized controlled trial. PLoS ONE. 2013;8(10): e76435.","journal-title":"PLoS ONE"},{"issue":"3","key":"8931_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/EDE.0000000000000435","volume":"27","author":"DA Young-Afat","year":"2016","unstructured":"Young-Afat DA, et al. Staged-informed consent in the cohort multiple randomized controlled trial design. Epidemiology. 2016;27(3):389\u201392.","journal-title":"Epidemiology"},{"key":"8931_CR7","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan, L., et al. An enhanced participant information leaflet and multimedia intervention to improve the quality of informed consent to a randomised clinical trial enrolling people living with HIV and obesity: a protocol for a Study Within A Trial (SWAT). Trials, 2022. 23(50).","DOI":"10.1186\/s13063-021-05979-y"},{"key":"8931_CR8","doi-asserted-by":"crossref","unstructured":"Treweek, S., et al., Strategies to improve recruitment to randomised trials. The Cochrane Library, 2018.","DOI":"10.1002\/14651858.MR000013.pub6"},{"issue":"supplement 1","key":"8931_CR9","doi-asserted-by":"publisher","first-page":"A111","DOI":"10.1186\/1745-6215-12-S1-A111","volume":"12","author":"F Chen","year":"2011","unstructured":"Chen F, et al. Investigating strategies to improve attendance at screening visits in a randomized trial. Trials. 2011;12(supplement 1):A111.","journal-title":"Trials"},{"issue":"9","key":"8931_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/jme.2010.041871","volume":"37","author":"EE Antoniou","year":"2011","unstructured":"Antoniou EE, et al. An empirical study on the preferred size of the participant information sheet in research. J Med Ethics. 2011;37(9):557\u201362.","journal-title":"J Med Ethics"},{"issue":"6","key":"8931_CR11","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1016\/S2589-7500(23)00052-3","volume":"5","author":"E Vayena","year":"2023","unstructured":"Vayena E, Blasimme A, Sugarman J. Decentralised clinical trials: ethical opportunities and challenges. The Lancet Digital health. 2023;5(6):e390\u20134.","journal-title":"The Lancet Digital health"},{"issue":"5","key":"8931_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/bmjebm-2023-112253","volume":"28","author":"OL Aiyegbusi","year":"2023","unstructured":"Aiyegbusi OL, et al. Digitally enabled decentralised research: opportunities to improve the efficiency of clinical trials and observational studies. BMJ Evidence-Based Medicine. 2023;28(5):328\u201331.","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"1","key":"8931_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/1471-2288-12-162","volume":"12","author":"E Mathieu","year":"2012","unstructured":"Mathieu E, et al. Internet trials: participant experiences and perspectives. BMC Med Res Methodol. 2012;12(1):162.","journal-title":"BMC Med Res Methodol"},{"key":"8931_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jclinepi.2021.01.014","volume":"134","author":"P Natale","year":"2021","unstructured":"Natale P, et al. Transparency, trust and minimizing burden to increase recruitment and retention in trials: a systematic review. J Clin Epidemiol. 2021;134:35\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"8931_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s13063-021-05466-4","volume":"22","author":"C Norton","year":"2021","unstructured":"Norton C, et al. Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency\/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. Trials. 2021;22(1):516.","journal-title":"Trials"},{"key":"8931_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s12876-024-03570-8","volume":"24","author":"A Hart","year":"2024","unstructured":"Hart A, Miller L, B\u00fcttner FC, et al. Fatigue, pain and faecal incontinence in adult inflammatory bowel disease patients and the unmet need: a national cross-sectional survey. BMC Gastroenterol. 2024;24:481.","journal-title":"BMC Gastroenterol"},{"key":"8931_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13063-024-08004-0","volume":"25","author":"CE Arundel","year":"2024","unstructured":"Arundel CE, et al. Trial Forge Guidance 4: a guideline for reporting the results of randomised Studies Within A Trial (SWATs). Trials. 2024;25:183.","journal-title":"Trials"},{"key":"8931_CR18","unstructured":"Crohn\u2019s & Colitis UK (2022). New research shows over 1 in 123 people in UK living with Crohn\u2019s or Colitis (crohnsandcolitis.org.uk)."},{"key":"8931_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jclinepi.2020.10.015","volume":"130","author":"DA Young-Afat","year":"2021","unstructured":"Young-Afat DA, et al. Oncology patients were found to understand and accept the Trials within Cohorts design. J Clin Epidemiol. 2021;130:135\u201342.","journal-title":"J Clin Epidemiol"},{"key":"8931_CR20","unstructured":"Improving inclusion of under-served groups in clinical research: Guidance from include project. NIHR. https:\/\/www.nihr.ac.uk\/documents\/improving-inclusion-of-under-served-groups-in-clinical-research-guidance-from-include-project\/25435#groups-by-demographic-factors-age-sex-ethnicity-education."},{"key":"8931_CR21","unstructured":"Inclusive research design to become an NIHR condition of funding. NIHR. https:\/\/www.nihr.ac.uk\/documents\/inclusive-research-design-to-become-an-nihr-condition-of-funding\/36278#:~:text=All%20research%20programmes%20will%20include,one%20of%20NIHR\u2019s%20operating%20principles."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08931-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08931-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08931-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:02:28Z","timestamp":1750230148000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08931-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8931"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08931-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This SWAT was granted favourable ethical opinion by the National Research Ethics Committee & Health Research Authority (London\u2014Surrey Research Ethics Committee\/19\/LO\/0750) as part of the ethical approval for the host RCT, including permission not to inform participants that they were randomised in the SWAT.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Laura Miller: None.Ailsa Hart: has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Galapogos, Lilly, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Global Steering Committee for Genentech.Fionn Cl\u00e9irigh-B\u00fcttner: None.Catherine Arundel: None.Thomas Hamborg: None.Serena McGuinness: None.Rona Moss-Morris: beneficiary of licence between King\u2019s College London and Mahana Therapeutics, consulting fees\u2014Mahana Therapeutics, 11 London. Payment or honoraria for lectures, presentations, or educational events\u2014EAPM and BABCP conferences, Central and North West London NHS Foundation Trust.Adwoa Parker: holds a NIHR Advanced Fellowship (NIHR302256), and received funding from the MRC and NIHR as part of being a co-applicant on this PROMETHEUS programme (MR\/R013748\/1).Clare Relton: None.Imogen Stagg: None.Louise Sweeney: None.Vari Wileman: None.Zohra Zenasni: None.Christine Norton: speakers fees from: Janssen; WebMD; Medscape; Merck Pharmaceuticals; Tillotts Pharma UK, Lilly Pharmaceuticals. Pfizer: advisory board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}